For the quarter ended September 2025, Jazz Pharmaceuticals (JAZZ) reported revenue of $1.13 billion, up 6.7% over the same period last year. EPS came in at $8.13, compared to $6.61 in the year-ago quarter.The reported revenue represents a surprise of +2.16% over the Zacks Consensus Estimate of $1.1 billion. With the consensus EPS estimate being $5.74, the EPS surprise was +41.64%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall ...

Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $8.13 per share, beating the Zacks Consensus Estimate of $5.74 per share. This compares to earnings of $6.61 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +41.64%. A quarter ago, it was expected that this drugmaker would post a loss of $6.12 per share when it actually produced a loss of $8.25, delivering a surprise of -34.8%.Over the last four quarters, the comp ...

Jazz Pharmaceuticals (NasdaqGS:JAZZ) Q3 2025 Earnings Call November 05, 2025 04:30 PM ET Speaker13Good day, and thank you for standing by. Welcome to the Jazz Pharmaceuticals 2025 Third Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press Star 11 on your telephone. You will then hear an automated message advising your hand is raise ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

November 5, 2025 EPIDIOLEX ® patient diagnosed with Dravet syndrome November 5, 2025 Markella Transforming Lives. Redefining Possibilities. Caution Concerning Forward-Looking Statements This presentation contains forward-looking statements and financial targets, including, but not limited to, statements related to: the Company's growth prospects and future financial and operating results, including the Company's 2025 financial guidance and the Company's expectations related thereto, including with respect t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 For the quarterly period ended September 30, 2025 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-33500 JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 (State or other ju ...

Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution: Exhibit 99.1 Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance DUBLIN, November 5, 2025 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2025 and updated financial guidance for 2025. "Achieving the highest revenue quarter in Jazz's history speaks to the strength of our diversified portfolio and the outstanding performance of our ...

Accessibility StatementSkip Navigation – Modeyso™ approved as the first and only treatment for recurrent H3 K27M-mutant DMG – – Zepzelcaand atezolizumab (Tecentriq) combination approved as maintenance therapy in 1L ES-SCLC – – 3Q25 total revenues increased 7% year-over-year driven by robust growth of Epidiolex, Xywavand the launch of Modeyso – DUBLIN, Nov. 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2025 and updated financial g ...

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .On Wednesday, Avadel Pharmaceuticals ( AVDL ) accepted a buyout off from Alkermes plc ( ALKS ) after settling litigation with Jazz Pharmaceuticals ( JAZZ ) . It should be noted this just the latest of several notable acquisitions sinceB ...

Accessibility StatementSkip Navigation DUBLIN, Oct. 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 third quarter financial results on Wednesday, November 5, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. EST / 9:30 p.m. GMT to discuss 2025 third quarter financial results and provide a business and financial update. Interested parties may register for the call in advance here ...